PDCD1 and hepatocellular carcinoma: Zheng et al. reported that fecal samples from patients who responded to ICI (n=3) during anti-PD-1 immunotherapy for HCC showed a higher Lactobacillus content in their intestinal microbiota than those who did not (n=5).